IP Library › Granted Patent US 7,682,615
Granted Patent B2
US 7,682,615 · App. 11/657,722 · Granted Mar 23, 2010

Immune modulating compounds from fungi

Assignee: BeKa Holding AS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,682,615
App. No.
11/657,722
Granted
Mar 23, 2010
Kind
B2
Abstract

The present invention relates to compositions comprising polypeptides and polysaccharides. The compositions are in general immune modulating. The invention also discloses methods of producing these compositions using filamentous fungi cultivated in liquid medium. The compositions are useful for example in the treatment of immune compromised conditions.

Claims (21)

1. An isolated, aqueous liquid immune stimulating composition comprising a mixture of polysaccharides comprising the monosaccharide units galactose, mannose and glucose,

wherein: the majority of the polysaccharides of the composition have a molecular weight of at least 1,000 Da wherein a first part of said polysaccharides have a molecular weight of less than 1,000,000 Da, wherein a second part of said polysaccharides have a molecular weight of at least 1,000,000 Da, wherein said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 1:0.033 to 500:1 to 50, and wherein the composition is produced by a method comprising the steps of;

a) cultivating a fungus of the genus Lentinus in a liquid growth medium under appropriate conditions to provide a suitable chemical and physical environment supporting the growth of a fungus of the genus Lentinus in the liquid growth medium,

b) isolating the composition from said liquid growth medium by one or more size fractionation steps, and

c) retaining said composition for further use.

2. The composition according to claim 1 , wherein the one or more size fractionation steps comprise a method involving ultracentrifugation, ultrafiltration, microfiltration or gel filtration.

3. The composition according to claim 1 , wherein the fungus of the genus Lentinus is Lentinus edodes.

4. The composition according to claim 1 , wherein the majority of the polysaceharides of the composition have a molecular weight of at least 50,000 Da.

5. The composition according to claim 1 , wherein the majority of the polysaccharides of the composition have a molecular weight of at least 100,000 Da.

6. A method of producing a composition according to claim 1 , said method comprising the steps of

a) cultivating a fungus of the genus Lentinus in a liquid growth medium under appropriate conditions to provide a suitable chemical and physical environment supporting the growth of a fungus of the genus Lentinus in a liquid growth medium, and

b) isolating the composition from said liquid growth medium by one or more size fractionation steps and retaining said composition for further use.

7. The method according to claim 6 , wherein said separation is achieved by a method step comprising ultracentrifugation, ultrafiltration, microfiltration or gel filtration.

8. A pharmaceutical composition comprising the composition according to claim 1 and a pharmaceutically acceptable carrier.

9. A method of treatment of an individual

i) diagnosed with an immune compromised condition; and/or

ii) at risk of contracting an immune compromised condition; and/or

iii) recovering from surgery or illness and at risk of contracting an immune compromised condition; and/or

iv) diagnosed with or at risk of contracting acquired immunodeficiency syndrome,

said method comprising the steps of administering to said individual the composition according to claim 1 in an amount effective in treating said immune compromised condition or said syndrome or effective in boosting the immune system of said individual.

10. A kit comprising the composition according to claim 1 and a dosage regime instruction with guidelines for dose and time administration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: BEKA HOLDING AS
To: GLYCANOVA AS
Reel/Frame 031460/0101 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2009
From: MEDIMUSH A/S
To: BEKA HOLDING AS
Reel/Frame 022886/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2008
From: KRISTIANSEN, BJORN
To: MEDIMUSH A/S
Reel/Frame 020548/0091 →
Continuity (5)
Continuation In Part 1089239300 · Jul 16, 2004
Provisional Application 6069049600 · Jun 15, 2005
Provisional Application 6069047700 · Jun 15, 2005
Provisional Application 6069048200 · Jun 15, 2005
Related Publication 20080031892A1 · Feb 7, 2008